News Center

Home page

Peak Report

News reports

Qiubin preparation workshop stock busy

Release time:

2021-07-01

6# January 18 , there was a busy scene in the Qiubin preparation workshop of Jianfeng Pharmaceutical. On the eye drops production line, with the operation of the machine, the white bottles filled one by one are transported out and neatly arranged in the stainless steel frame, waiting to be sent to the next process; in the clean area, the employees "are fully armed " , paying close attention to the filling situation; packing, packing, coding ... In each production position, the employees perform their duties and are busy in an orderly manner.

In recent years, with the influence of various factors such as the aging of my country's population, lifestyle changes, increased work intensity, increased allergens, and improper eye use, the incidence of various eye diseases has increased year by year, and the market for ophthalmic drugs The growth is fast, and anti-allergic drugs and macular degeneration drugs are the fast-growing ophthalmic drugs. Spike Pharmaceutical's olopatadine hydrochloride eye drops is a drug for the treatment of allergic conjunctivitis. It is the first of its kind in China to pass the consistency evaluation and won the bid in the fourth batch of national drug centralized procurement in 2 this year. In the procurement cycle, medical institutions will give priority to the use of drugs selected in centralized procurement. 5 June, the new standard began to be implemented. According to the sales plan, Jianfeng Pharmaceutical adjusted the production arrangement scientifically and reasonably to ensure stable market supply.

According to Wang Xiizhong, director of Qiubin Preparation Workshop, the production of olopatadine eye drops takes about hours to complete a batch of production from the production preparation of raw and auxiliary materials to the packaging requirements. Under normal circumstances, it takes about 11 hours to complete a batch of production, plus equipment cleaning and sterilization. The preparation workshop started to produce two batches of olopatadine eye drops a day from 6 May 10 , and completed one cycle of production by 18 . The employees are divided into two shifts, one shift a day, working from 6 in the morning to the end of 3: 4 a.m. the next day. sometimes the clearance is slightly delayed. the first shift has just left work, and the second shift is already preparing for the production of the day.

In order to ensure the smooth progress of the production task, in addition to the personnel in the preparation workshop, the First Manufacturing Department adjusted the production arrangement of Jinxi Powder Injection Workshop, and the adjustment personnel came to support the production and packaging of eye drops first. In order to solve the problems in production in time, the team members of the first manufacturing department took turns on duty and worked overtime until early morning with the employees. Considering the busy production, it is early morning after work, moreover, some employees are far away from home. In order to ensure that employees have enough rest time, the First Manufacturing Department specially applied for two dormitories to work shifts. Because this rush is the first large-scale stock after olopatadine won the bid for centralized procurement, the leaders of the group company and the pharmaceutical company attach great importance to it and go to the production site many times to understand the situation and visit the overtime workers. Pharmaceutical companies have also given a lot of support for production deployment and other aspects.

In order to solve the imbalance of product output and production in each workshop, the First Manufacturing Department has organized mutual learning and training for employees in different workshops and positions in recent years, with the aim of adjusting each other when workshop production is tight or production plans are temporarily adjusted. Zheng Kunwu, manager of the first manufacturing department, said that according to the market situation of olopatadine eye drops, the first manufacturing department will consider updating some equipment to expand production capacity, improve work efficiency and reduce labor costs. At the same time, it will further strengthen the training of one person and multiple posts to ensure sufficient personnel in key positions. (Reporter Ni Yingzhen)

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页